CrossrefInfokarte
Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC
European Journal of Cancer · 2026-12 · 249 · 117812
DOI: 10.1016/j.ejca.2026.117812 ↗Abstract
Kein Abstract verfügbar.
EUVIMED